{"id":111613,"name":"EAVE II","nav":[{"children":[{"children":[],"id":111630,"title":"Our research team"},{"children":[{"children":[],"id":142561,"title":"EAVE II Patient and Public Involvement Report (Plain Text)"}],"id":126837,"title":"Our Public Advisory Group (PAG)"}],"id":126832,"title":"Meet our team"},{"children":[],"id":143193,"title":"News mentions & appearances"},{"children":[{"children":[{"children":[],"id":135109,"title":"Meet the team"},{"children":[],"id":135110,"title":"Funders and Partners"},{"children":[],"id":135108,"title":"About us"},{"children":[],"id":135111,"title":"Research Outputs"}],"id":135107,"title":"Vaccine Booster Breakthroughs"},{"children":[{"children":[],"id":138133,"title":"Meet the COALESCE Team"},{"children":[],"id":138134,"title":"Our Funders and Partners"},{"children":[],"id":138132,"title":"About COALESCE"},{"children":[],"id":138727,"title":"COALESCE Publications"}],"id":138131,"title":"COALESCE"},{"children":[],"id":138770,"title":"CHILDS"},{"children":[{"children":[],"id":135972,"title":"Meet our team"},{"children":[],"id":135966,"title":"About DaC-VaP-2"},{"children":[],"id":137476,"title":"Our Publications"},{"children":[],"id":140506,"title":"Watch our webinar"},{"children":[],"id":135967,"title":"Funders and Partners"}],"id":135963,"title":"DaC-VaP-2"},{"children":[{"children":[],"id":144573,"title":"Scottish Parliament Long COVID Inquiry"},{"children":[],"id":143819,"title":"Meet the team"},{"children":[],"id":143798,"title":"About Long COVID"},{"children":[],"id":143190,"title":"Project outputs"},{"children":[],"id":144166,"title":"Funders & Partners"}],"id":143797,"title":"Long COVID"},{"children":[{"children":[],"id":135946,"title":"Meet our team"},{"children":[],"id":140650,"title":"Our publications and outputs"},{"children":[],"id":140968,"title":"Listen to our soundbites"},{"children":[],"id":135948,"title":"Our Funders and Partners"},{"children":[],"id":136031,"title":"About Vaccine Breakthroughs"}],"id":135945,"title":"Vaccine Breakthroughs Project"},{"children":[],"id":126818,"title":"Quick access list of connected projects"},{"children":[{"children":[],"id":135980,"title":"About DaC-VaP"},{"children":[],"id":135998,"title":"Our Publications"},{"children":[],"id":135995,"title":"Meet our team"},{"children":[],"id":135997,"title":"Funders and Partners"}],"id":135976,"title":"DaC-VaP"},{"children":[],"id":136034,"title":"ROCOVE"},{"children":[],"id":136040,"title":"COPS"},{"children":[],"id":135982,"title":"What are connected projects?"}],"id":135106,"title":"Connected projects"},{"children":[],"id":143191,"title":"Awards & Recognitions"},{"children":[{"children":[],"id":111643,"title":"Funders and Partners"},{"children":[],"id":128293,"title":"Code List Library"},{"children":[],"id":111628,"title":"An Introduction to EAVE II"},{"children":[],"id":111631,"title":"The History of EAVE II"},{"children":[],"id":111633,"title":"EAVE II data"}],"id":126788,"title":"About EAVE II"},{"children":[{"children":[],"id":143436,"title":"Meetings with Government"},{"children":[],"id":126830,"title":"Scottish Government reports"},{"children":[],"id":144574,"title":"Scottish Parliament Long COVID Inquiry"}],"id":143368,"title":"Informing policy"},{"children":[{"children":[{"children":[],"id":126821,"title":"Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland"},{"children":[],"id":126822,"title":"Pre-print of COVID-19 Vaccines Effectiveness in Scotland paper"},{"children":[],"id":144497,"title":"Identifying Long Covid Using Electronic Health Records"},{"children":[],"id":137332,"title":"Pre-print: Waning of BNT162b2 or ChadOx1 mRNA Boosters against symptomatic infection and severe COVID-19 in Brazil and Scotland"},{"children":[],"id":130596,"title":"Neurological complications after first dose of COVID-19 vaccination and SARS-CoV-2 infection"},{"children":[],"id":130195,"title":"COVID-19 hospital admissions and deaths post BNT162b2 and ChAdOx1 vaccinations: National prospective cohort study of 2.57 million people in Scotland"},{"children":[],"id":133782,"title":"External validation of the QCovid risk prediction algorithm for risk of COVID-19 hospitalisation and mortality in adults: national validation cohort study in Scotland"},{"children":[],"id":133015,"title":"Severity of Omicron variant of concern and vaccine effectiveness against symptomatic disease"},{"children":[],"id":127979,"title":"Impact of COVID-19 lockdown on emergency asthma admissions and deaths: national interrupted time series analyses for Scotland and Wales"},{"children":[],"id":127978,"title":"Impact of COVID-19 Lockdown on the Incidence and Mortality of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: National Interrupted Time Series Analyses for Scotland and Wales"},{"children":[],"id":138832,"title":"Effectiveness of Two-Dose Pfizer-BioNTech vaccine among Adolescents  in Scotland and Brazil"},{"children":[],"id":135009,"title":"Retrospective cohort study to evaluate medication use in patients hospitalised with COVID-19 in Scotland: protocol for a national observational study"},{"children":[],"id":137042,"title":"Impact on emergency and elective hospital-based care in Scotland over the first year of the pandemic"},{"children":[],"id":127980,"title":"Protocol: EAVE II Study"},{"children":[],"id":131782,"title":"Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland"},{"children":[],"id":126828,"title":"Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from COVID-19 in adults: national derivation and validation cohort study"},{"children":[],"id":132419,"title":"Risk of COVID-19 hospital admission among children aged 5–17 years with asthma in Scotland: a national incident cohort study"},{"children":[],"id":133778,"title":"SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland"},{"children":[],"id":133258,"title":"Risk of serious COVID-19 outcomes among adults with asthma in Scotland: a national incident cohort study"},{"children":[],"id":134578,"title":"Uptake of infant and preschool immunisations in Scotland and England during the COVID-19 pandemic"},{"children":[],"id":136071,"title":"Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland"},{"children":[],"id":129014,"title":"Ethnic and social inequalities in COVID-19 outcomes in Scotland: protocol for early pandemic evaluation  and enhanced surveillance of COVID-19 (EAVE II)"},{"children":[],"id":127906,"title":"Temporal trends and forecasting of COVID-19 hospitalisations and deaths in Scotland using a national real-time patient-level data platform: a statistical modelling study"},{"children":[],"id":140318,"title":"BNT162b2 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people aged 12–17 years in Scotland"},{"children":[],"id":137472,"title":"Protocol: Investigating the uptake, effectiveness and safety of COVID-19 vaccines"},{"children":[],"id":142002,"title":"Risk of COVID-19 hospitalizations among school-aged children in Scotland"},{"children":[],"id":140762,"title":"Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters"},{"children":[],"id":141321,"title":"COPS: Early Pregnancy Outcomes following COVID-19 Vaccination and SARS-COV-2 Infection in Pregnant Women"},{"children":[],"id":126884,"title":"First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland."},{"children":[],"id":129008,"title":"Predicted COVID-19 positive cases, hospitalisations, and deaths associated with the Delta variant of concern, June–July, 2021 (EURO 2020)"},{"children":[],"id":142003,"title":"Letter: Severity of Omicron BA.2 variant and vaccine effectiveness against symptomatic disease in Scotland"},{"children":[],"id":131018,"title":"Association between multimorbidity and mortality in a cohort of patients admitted to hospital with COVID-19 in Scotland"},{"children":[],"id":136659,"title":"First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis"},{"children":[],"id":126823,"title":"Impact of COVID-19 on accident and emergency attendances and admissions in Scotland"},{"children":[],"id":127078,"title":"SARS-CoV-2 Delta VOC  in Scotland: demographics, risk of hospital admission, and vaccine effectiveness"},{"children":[],"id":137947,"title":"Pre-print: Obesity is associated with reduced SARS-CoV-2 vaccine efficacy"},{"children":[],"id":127128,"title":"Cohort profile: Early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II) database"},{"children":[],"id":135409,"title":"BNT162b2 and ChAdOx1 nCoV-19 Vaccinations, Incidence of SARS-CoV-2 Infections and COVID-19 Hospitalisations in Scotland in the Delta era"},{"children":[],"id":140706,"title":"Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations across the UK"},{"children":[],"id":141390,"title":"COVID-19 in Pregnancy in Scotland (COPS): protocol for an observational study using linked Scottish national data"},{"children":[],"id":142941,"title":"Study of major congenital anomalies following COVID-19 vaccination and SARS-CoV-2 infection"},{"children":[],"id":126820,"title":"Quick Access List"},{"children":[],"id":142445,"title":"Assessing medication use patterns in patients hospitalised with COVID-19: a retrospective study"},{"children":[],"id":142800,"title":"Confirmed SARS-CoV-2 infection in Scottish newborns 2020–2022"},{"children":[],"id":135663,"title":"Vaccine Effectiveness of Two-Dose BNT162b2 Over Time Against COVID-19 Symptomatic Infection and Severe Cases Among Adolescents"},{"children":[],"id":135008,"title":"Uptake, effectiveness and safety of COVID-19 vaccines in children and young people in Scotland: Protocol for early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II)"},{"children":[],"id":135114,"title":"Uptake of monoclonal antibodies and anti-viral therapies for COVID-19 in Scotland"},{"children":[],"id":137116,"title":"Impact of first UK COVID-19 lockdown on hospital admissions in England, Scotland and Wales"},{"children":[],"id":142943,"title":"Effectiveness of mRNA boosters against symptomatic infection and severe COVID-19 in Brazil and Scotland"},{"children":[],"id":140238,"title":"Characterising adults in Scotland who are not vaccinated against COVID-19"},{"children":[],"id":142522,"title":"Spotlight: Patient collaboration in COVID-19 research: translating ideas to reality"},{"children":[],"id":139125,"title":"Second-dose Oxford-AstraZeneca and Pfizer-BioNTech vaccines and blood clotting and bleeding events in Scotland"},{"children":[],"id":132985,"title":"Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time in Scotland & Brazil"},{"children":[],"id":130920,"title":"Vaccine Efficacy against the Delta Variant in Scotland"},{"children":[],"id":137707,"title":"Protocol: Common protocol for validation of the QCOVID algorithm across the four UK nations"},{"children":[],"id":140707,"title":"Pregnancy outcomes following Delta and Omicron SARS-CoV-2 infection in Scotland"}],"id":126819,"title":"Research Publications"},{"children":[],"id":143631,"title":"Patient & Public Involvement Report (EAVE II)"},{"children":[],"id":143485,"title":"Infographics"},{"children":[],"id":126853,"title":"Protocol and Analyses"},{"children":[],"id":144079,"title":"Research Insights: health data - what's in it for you?"}],"id":121473,"title":"Key outputs"}],"parent":"Usher Institute"}